The estimated Net Worth of Mark Mallon is at least $11 Million dollars as of 6 December 2021. Mr. Mallon owns over 17,000 units of Ironwood Pharmaceuticals Inc stock worth over $316,402 and over the last 6 years he sold IRWD stock worth over $612,485. In addition, he makes $10,068,800 as Chief Executive Officer and Director at Ironwood Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Mallon IRWD stock SEC Form 4 insiders trading
Mark has made over 4 trades of the Ironwood Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 17,000 units of IRWD stock worth $520,710 on 6 December 2021.
The largest trade he's ever made was selling 30,675 units of Ironwood Pharmaceuticals Inc stock on 26 February 2021 worth over $279,449. On average, Mark trades about 7,887 units every 65 days since 2019. As of 6 December 2021 he still owns at least 72,736 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Mr. Mallon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Mallon biography
Mark Mallon is Chief Executive Officer, Director of the company. Prior to joining Ironwood in January 2019 as executive senior advisor and becoming chief executive officer of Ironwood in April 2019, Mr. Mallon was a member of the senior executive team of AstraZeneca PLC and led certain key strategic functions: global product and portfolio strategy, global medical affairs, and corporate affairs. After joining AstraZeneca in 1994, Mr. Mallon held a number of senior sales and marketing roles, including executive vice president, international from January 2013 to April 2017 and executive vice president, global product and portfolio strategy from August 2016 to December 2018. Mr. Mallon started his career in the biopharmaceutical industry in management consulting Mr. Mallon earned his B.S. in chemical engineering from the University of Pennsylvania and his M.B.A. in marketing and finance from the Wharton School of Business. Given his role as our chief executive officer, we believe Mr. Mallon brings unique and in-depth insight on the operations and management of the company, which together with Mr. Mallon's extensive experience building and shaping businesses, and his deep knowledge of GI, is valuable to our board of directors.
What is the salary of Mark Mallon?
As the Chief Executive Officer and Director of Ironwood Pharmaceuticals Inc, the total compensation of Mark Mallon at Ironwood Pharmaceuticals Inc is $10,068,800. There are no executives at Ironwood Pharmaceuticals Inc getting paid more.
How old is Mark Mallon?
Mark Mallon is 57, he's been the Chief Executive Officer and Director of Ironwood Pharmaceuticals Inc since 2019. There are 10 older and 8 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.
What's Mark Mallon's mailing address?
Mark's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Insiders trading at Ironwood Pharmaceuticals Inc
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts, and Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
What does Ironwood Pharmaceuticals Inc do?
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
What does Ironwood Pharmaceuticals Inc's logo look like?
Complete history of Mr. Mallon stock trades at Ironwood Pharmaceuticals Inc and Neogenomics
Ironwood Pharmaceuticals Inc executives and stock owners
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Mark Mallon,
Chief Executive Officer, Director -
Thomas McCourt,
President -
Mark Currie,
Director -
Gina Consylman,
Chief Financial Officer, Senior Vice President -
Thomas A. McCourt,
CEO & Director -
Jason Rickard,
COO & Sr. VP of Operations -
Dr. Michael Shetzline M.D., Ph.D.,
Chief Medical Officer, Sr. VP and Head of R&D -
Catherine Moukheibir,
Independent Director -
Jon Duane,
Independent Director -
Marla Kessler,
Independent Director -
Julie McHugh,
Independent Chairman of the Board -
Andrew Dreyfus,
Independent Director -
Edward Owens,
Independent Director -
Lawrence Olanoff,
Independent Director -
Julie H. McHugh,
Exec. Chairman -
Alexander Denner,
Director -
Meredith Kaya,
Vice President - Investor Relations and Corporate Communications -
Michael Shetzline,
Chief Medical Officer, Senior Vice President and Head of Drug Development -
Conor Kilroy,
Senior Vice President, General Counsel -
Jason Rickard,
Chief Operating Officer, Senior Vice President -
John Minardo,
Sr. VP & Chief Legal Officer -
Marcel Moulaison,
VP of Technical Operations -
Ronald Silver,
Corp. Controller & Principal Accounting Officer -
Sravan Kumar Emany,
Sr. VP & CFO -
G. Todd Milne,
Co-Founder and VP of sGC R&D -
Brian M. Cali,
Co-Founder and Sr. VP of R&D Strategy & External Innovation -
Terrance Mcguire,
Director -
Douglas E Williams,
Director -
Amy W Schulman,
Director -
Marsha Fanucci,
Director -
Christopher T Phd Walsh,
Director -
Peter M Hecht,
Chief Executive Officer -
Thomas Graney,
Chief Financial Officer -
William Huyett,
Chief Operating Officer -
Halley E Gilbert,
Chief Admin Officer & SVP -
Bryan E Roberts,
Director -
Associatesvenrock Associate...,
-
Management Llc Vr,
10% owner -
Llc Fmr,
10% owner -
Llcfil Ltd Fmr,
-
Co Investment Holdings, Llc...,
-
Capital Investments L.P.Rid...,
-
Joseph C Jr Cook,
Director -
George H Conrades,
Director -
David Evans Shaw,
Director -
David A Ebersman,
Director -
Michael J Higgins,
Chief Operating Officer -
Kelly Mac Donald,
Chief Accounting Officer -
Jay Shepard,
-
Sravan Kumar Emany,
SVP, Chief Financial Officer -
Alexander J Sarissa Capital...,
-
Andrew Davis,
SVP, Chief Business Officer -
Ronald Silver,
Principal Accounting Officer -
Minardo John,
Chief Legal Officer